Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INCAGN01876 + retifanlimab
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
INCAGN01876 + retifanlimab is a **combination immunotherapy** under investigation primarily for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). - **INCAGN01876** (ragifilimab) is a monoclonal antibody that acts as a **GITR (Glucocorticoid-induced tumor necrosis factor receptor) agonist**, promoting anti-tumor immune responses by activating effector T cells and depleting regulatory T cells[4]. - **Retifanlimab** (Zynyz, retifanlimab-dlwr) is a monoclonal antibody targeting **PD-1 (Programmed cell death 1)**, functioning as a checkpoint inhibitor that restores T cell activity against tumor cells[3]. Developed for cancers such as HNSCC, the combination is being assessed for safety, tolerability, pharmacokinetics, and efficacy in phase 2 clinical trials[1][2].
- Brand names
- Zynyz
- Other names
- ragifilimab (for INCAGN01876)retifanlimab-dlwr
02
Targets
TNFRSF18 (GITR)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on INCAGN01876 + retifanlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INCAGN01876 + retifanlimab.